3 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 2 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
Follow Astrocytoma, IDH-Mutant, Grade 3: new trials by email Literature Review of Astrocytoma, IDH-Mutant, Grade 3 trials Research Report on Astrocytoma, IDH-Mutant, Grade 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning - Astrocytoma, IDH-Mutant, Grade 3 | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 408 | 2026-06-24 | 2026-10-02 |
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) safusidenib, Placebo - Glioma, Astrocytoma, Grade IV | Phase 3 | Recruiting | Nuvation Bio Inc. | 365 | 2023-06-05 | 2026-10-19 |
| Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride - Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 23 | 2019-05-01 | 2026-09-22 |
| GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3) GliomaAI-Astro23 - Glioma, Glioma (Diagnosis) | Completed | Deep Learning Institute of Radiological Sciences | 1372 | 2017-03-14 | 2026-06-29 |
Astrocytoma (6) · Lymphoma, Follicular (6) · Glioma (4) · Glioblastoma (3) · Brain Neoplasms (2) · Oligodendroglioma (2) · Disease (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Nerve Tissue (6) · Neoplasms, Neuroepithelial (6) · Neuroectodermal Tumors (6) · Brain Diseases (2)
Temozolomide (3) · Magnetic Resonance Spectroscopy (2) · Eflornithine (1) · Imiquimod (1) · Radiation (1) · Radiotherapy (1) · Radiotherapy, Intensity-Modulated (1) · Specimen Handling (1) · Spinal Puncture (1) · Transurethral Resection of Bladder (1) · vorasidenib (1)
Alliance for Clinical Trials in Oncology (1) · Deep Learning Institute of Radiological Sciences (1) · German Cancer Research Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Nuvation Bio Inc. (1)
United States (4) · Australia (1) · China (1) · Germany (1) · India (1)
Michael Platten, Prof. Dr. med. (1) · Patrick Y Wen, MD (1) · Rifaquat M. Rahman, MD (1) · Sani H Kizilbash (1) · Terence C. Burns, MD, PhD (1) · Ugonma N Chukwueke, MD (1)
UM1CA186686 (1), UM1CA186709 (1)